stars 1 stars 2 stars 3

Ukko is a biotechnology company dedicated to designing safe immunotherapies to rapidly treat allergies and other immune-mediated conditions. Our proprietary technology platform has the potential to reduce or eliminate potentially dangerous allergic reactions, while inducing a protective immune response. By rethinking how to prevent allergic reactions at the molecular level, we aim to develop a safer, more precise alternative to traditional allergy desensitization methods, starting with individuals at risk for life-threatening allergic reactions to peanut.

Ukko Questions

The Ukko annual revenue was $9.1 million in 2026.

Matt Ottmer is the COO of Ukko.

24 people are employed at Ukko.

Ukko is based in Boston, Massachusetts.

Top Ukko Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users